After Record-Breaking PC Launch in 2017, PC Community to Receive Destiny 2 Free
Destiny 2 has attracted legions of dedicated fans and has been enjoyed by millions of gamers around the world since launching in 2017. Now, that fanbase is set to grow as new Guardians will be able to enter the world of Destiny 2 for free in November. To celebrate an entire year on PC, Bungie and Activision, in collaboration with Blizzard Entertainment, announce that from November 2nd to November 18th everyone on Blizzard’s Battle.net gaming platform who has not already purchased Destiny 2—or any new members joining Battle.net—will have the opportunity to claim the game as a free gift.
Destiny 2 will be available on the Battle.net app to claim for free for a little more than two weeks in November, and players will have the opportunity to download the game once they’ve claimed it*. New Battle.net accounts created after 11:00 a.m. PDT on November 2, 2018, will be required to enable Blizzard SMS Protect before claiming their game license. Destiny 2 is redeemable from https://account.blizzard.com/gifts/.
Existing players of Destiny 2 PC will receive an exclusive emblem not available anywhere else, which becomes available in December, to commemorate the first anniversary of being on Battle.net. Additionally, new Guardians will have the opportunity to try out Destiny 2: Forsaken’s new mode “Gambit,” from November 9th through 11th 2018, during the Gambit Free Weekend. Gambit is a 4v4 hybrid activity included with Destiny 2: Forsaken. More details are available at http://www.DestinyTheGame.com/Battlenet/.
“We know Destiny players that want to play on PC expect an amazing experience, whether it’s on their own or with their friends -- so, our paramount concern was to keep the discerning requirements of the PC community in mind, and welcoming the Battle.net and Bungie PC communities together,” said Steve Cotton, game director for Destiny 2: Forsaken at Bungie. He added, “With this gift we look forward to seeing new Guardians in our universe.”
The genre-defining Destiny franchise has received global acclaim since its release in 2014, followed by a record-breaking Destiny 2’s PC launch in 2017, the largest PC launch in Activision Publishing history based on units. Developed by Bungie, and brought to PC in partnership with Vicarious Visions, Destiny 2 delivers a native PC experience with PC-specific features such as: 4K resolution support, uncapped frame rate, full mouse and keyboard support with custom key mapping, text chat, adjustable field of view, a detailed PC settings screen, 21:9 and triple monitor support, and HDR. In the story of Destiny 2, the last city on Earth has fallen and lies in ruins. Players must master new abilities and weapons to reunite the city's forces, stand together and fight back to reclaim their home.
Destiny 2 PC is playable on Windows 7, Windows 8, and Windows 10. Minimum system requirements for the PC game are an Intel Core i3-3250, Intel Pentium G4560, or an AMD FX-4350, along with a GeForce GTX 660 2GB, GTX 1050 2GB, or Radeon HD 7850. Additionally, 6GB of RAM, and 104GB of HDD space and internet connection are required.
For more game information, visit www.DestinyTheGame.com and follow the official Destiny social channels on Facebook and @DestinyTheGame on Instagram and Twitter. The community can interact directly with the developers at www.Bungie.net, Facebook, @Bungie on Twitter, Instagram and www.Twitch.tv/Bungie on Twitch.
About Bungie
Bungie is an independent, employee-owned game development studio dedicated to creating hopeful worlds that inspire passionate player communities and lifelong friendships. For more than two-and-a-half decades that purpose has led to the creation of some of the industry's most celebrated gaming franchises, including Marathon, Myth, Halo, and Destiny. Today, Bungie is focused on developing the next highly anticipated release in the Destiny universe and new worlds to come.
About Blizzard Entertainment, Inc.
Best known for blockbuster hits including World of Warcraft ®, Hearthstone ®, Overwatch ®, the Warcraft ®, StarCraft ®, and Diablo ® franchises, and the multi-franchise Heroes of the Storm ®, Blizzard Entertainment, Inc. (www.blizzard.com), a division of Activision Blizzard (NASDAQ: ATVI), is a premier developer and publisher of entertainment software renowned for creating some of the industry’s most critically acclaimed games. Blizzard Entertainment’s track record includes twenty-two #1 games and multiple Game of the Year awards. The company's online gaming service, Blizzard Battle.net®, is one of the largest in the world, with millions of active players.
About Activision
Headquartered in Santa Monica, Calif., Activision is a leading global producer and publisher of interactive entertainment. Activision maintains operations throughout the world and is a division of Activision Blizzard (NASDAQ: ATVI), an S&P 500 company. More information about Activision and its products can be found on the company’s website, www.activision.com or by following @Activision.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves Activision Publishing's expectations, plans, intentions or strategies regarding the future, including statements about the availability, dates and features of the Destiny 2 free gift, exclusive emblem and Gambit Free Weekend, are forward-looking statements that are not facts and involve a number of risks and uncertainties. Factors that could cause Activision Publishing's actual future results to differ materially from those expressed in the forward-looking statements set forth in this release include unanticipated product delays and other factors identified in the risk factors sections of Activision Blizzard's most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q. The forward-looking statements in this release are based upon information available to Activision Publishing and Activision Blizzard as of the date of this release, and neither Activision Publishing nor Activision Blizzard assumes any obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Activision Publishing or Activision Blizzard and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
*offer may not be available in every region
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005525/en/
Contact information
Activision
Genevieve Waldman
425-440-6854
gwaldman@activision.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom